Inhibition of FXa could be a novel therapeutic target associated with hypoxia-associated tumor behavior?

Özge Bayrak; Nazlı Mert; Yasemin Basbinar; Serdar Bayrak

doi:10.1007/s12672-025-02403-8

November 21, 2025Discover OncologyOpen Access

Inhibition of FXa could be a novel therapeutic target associated with hypoxia-associated tumor behavior?

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research explores the potential of Rivaroxaban to function as both an anticoagulant and anticancer agent in colorectal cancer (CRC).
Investigated the effects of Rivaroxaban under both hypoxic and normoxic conditions.
Analyzed its impact on tumor behavior of CRC.
Evaluated the anticoagulant properties in conjunction with anticancer effects.
Rivaroxaban shows effectiveness as an anticancer agent in CRC.
Demonstrated potential benefits under hypoxic conditions.
Proposed Rivaroxaban as a novel therapeutic target in cancer treatment.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Findings demonstrate that Rivaroxaban may improve outcomes in CRC by inhibiting hypoxia-associated tumor behavior, suggesting a novel therapeutic target.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bayrak et al. (2025) studied this question.

synapsesocial.com/papers/6924e3f2c0ce034ddc34f08a https://doi.org/10.1007/s12672-025-02403-8

View Full Paper

Ask AI

Bookmark

Share

Inhibition of FXa could be a novel therapeutic target associated with hypoxia-associated tumor behavior?

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Inhibition of FXa could be a novel therapeutic target associated with hypoxia-associated tumor behavior?

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading